Thomas L. Lisle

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells.

Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells.

Journal: Signal transduction and targeted therapy

Published: November 28, 2025

Harnessing Arginase-2-specific CD8+ T cells to target immunosuppressive Cutaneous T cell Lymphoma.

Harnessing Arginase-2-specific CD8+ T cells to target immunosuppressive Cutaneous T cell Lymphoma.

Journal: The British journal of dermatology

Published: July 01, 2025

Harnessing arginase 2-specific CD8+ T cells to target immunosuppressive cutaneous T-cell lymphoma.

Harnessing arginase 2-specific CD8+ T cells to target immunosuppressive cutaneous T-cell lymphoma.

Journal: The British journal of dermatology

Published: July 01, 2025

TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.

TGF-β-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.

Journal: Leukemia

Published: May 16, 2025

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.

Journal: Frontiers in immunology

Published: June 15, 2023

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.

Journal: Journal for immunotherapy of cancer

Published: February 27, 2023

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.

Journal: Frontiers in immunology

Published: December 06, 2022

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.

Journal: Journal for immunotherapy of cancer

Published: September 22, 2022

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.

Journal: Frontiers in oncology

Published: August 19, 2022

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Journal: Science translational medicine

Published: June 15, 2022

Sortilin Modulates Schwann Cell Signaling and Remak Bundle Regeneration Following Nerve Injury.

Sortilin Modulates Schwann Cell Signaling and Remak Bundle Regeneration Following Nerve Injury.

Journal: Frontiers in cellular neuroscience

Published: January 17, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026